Mobile website
Archive > Volume 24 Issue 2 > 2017,24(2):117-121. DOI:10.3872/j.issn.1007-385X.2017.02.003 Prev Next
Basic Research
Promoting apoptosis effect of natural killer cell amplificated ex vivo, which derived from human umbilical cord blood, on esophageal cancer cells
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To establish a method for amplification ex vivo of natural killer (NK) cells derived from human umbilical cord blood and to investigate cytokilling effect of the NK cell on multiple cell lines of human esophageal cancer and primary generation tumor cells of the patients with esophageal cancer. Methods: Human cord blood mononuclear cells (CBMC) were isolated and, irradiated inactivation human leukemia K562 cell and IL-2, IL-15, IL-18 cytokines were added into to amplify NK cells in culture ex vivo for 2 weeks. Amplification results of the NK cells and killing ability of secreted cytolines IFN-γ and so on against the target K562 cell were detected by Flow cytometry assay. Effect of NK cell amplificated ex vivo from human umbilical cord blood on apoptosis of various esophageal cancer cell lines and primary generation cancer cell of the patients with esophageal cancer were examined. Results: Irradiated inactivation K562 cell combined with multiple cytokines can effectively amplified NK cell derived from human umbilical cord blood. After culture ex vivo for 2 weeks, percentage of the NK cell can reach about 80% and had obviously promoting apoptosis of the K562 cell. In addition, amplification ex vivo NK cell derived from human umbilical cord blood can promote apoptosis of the 6 cell lines of human esophageal cancer and the primary generation cancer cell of the patients with esophageal cancer. Conclusion: In the study, the method of amplification ex vivo of NK cells derived from human umbilical cord blood was successfully established. The promoting apoptosis effect of the NK cells on esophageal cancer cells might be confirmed. It could provide a novel approach for immunotherapy of esophageal cancer.
Keywords:
Project Supported:
Project supported by the Foundation of Basic Science and Fronifer Technology Research Program of Henan Province（No.142300410387.0）
Clc Number:
